Official blog
Compliance-aware guides and brand updates for adult consumers.
Page 28 of 35 / 832 articles
Nicotine salts transformed vaping—making high-nicotine e-liquids palatable, enabling the pod-device revolution, and changing the pharmacokinetics of nicotine delivery. It's a story of chemistry, commerce, and unintended consequences.
Current youth anti-vaping messaging is failing because it treats teens as rational actors who will respond to risk information. What would a neuroscience-informed, teen-centered communication strategy look like?
E-cigarettes were barely on the public health radar. The FCTC was still finding its feet. And the seeds of the modern nicotine landscape were just being planted. A look back at the year that set the stage for everything that followed.
Imagine the final cigarette ever smoked. Who smokes it, and why? The thought experiment reveals uncomfortable truths about nicotine policy, human nature, and what we're really trying to achieve.
Tobacco cultivation, curing, and manufacturing contribute significantly to greenhouse gas emissions, deforestation, and environmental degradation. The industry's climate footprint is substantial—and almost entirely absent from climate policy discussions.
Some smokers try everything—NRT, varenicline, counseling, vaping—and still can't quit. Neuroscience is beginning to explain why, and the explanation points toward more personalized, more intensive approaches.
New Zealand's smokefree generation law was passed, celebrated globally, and then repealed within a year. What does this extraordinary policy rollercoaster teach us about the politics of tobacco endgame strategies?
Facebook, Google, and payment processors have become de facto regulators of the vaping industry—restricting advertising, blocking sales, and freezing accounts. The power of platforms to shape nicotine policy is enormous and largely unaccountable.
Two years after nicotine pouches went mainstream, the data is beginning to clarify the public health impact. The results so far: mostly positive, with important caveats that demand regulatory attention.
A smoker whose partner quits is far more likely to quit themselves. A smoker whose partner smokes faces dramatically higher odds of relapse. The social network is as powerful as any pharmacological intervention.
Australia pioneered plain packaging in 2012, facing down industry lawsuits and trade challenges. A decade later, over 20 countries have followed. The evidence is in: plain packaging works—and the industry's predictions of disaster were wrong.
In 2019, the U.S. raised the federal minimum age for tobacco sales to 21. Five years of data later, the results are in, and they're both encouraging and complicated.
Nicotine has measurable pain-relieving effects, which helps explain why smoking rates are elevated among chronic pain patients. Understanding this connection is essential for addressing one of the most refractory smoking populations.
A second journey through the nicotine landscape confirms the patterns from the first: complexity resists simplification, institutions lag behind evidence, and the human dimension of addiction demands compassion.
Your spouse, parent, or adult child has switched from smoking to vaping. You're worried, confused, and not sure what to say. Here's what the evidence says about supporting—not sabotaging—their transition.
Across Latin America, the tobacco industry has perfected a set of strategies to delay, weaken, and defeat tobacco control legislation. The playbook is consistent across countries—and it's devastatingly effective.
Five years ago, the evidence on passive vaping was thin and contested. Since then, a substantial body of research has emerged—and it's changing how policymakers and venue operators think about indoor vaping.
For decades, researchers have pursued a vaccine that would block nicotine from reaching the brain, making smoking unrewarding and quitting effortless. The science is tantalizing. The clinical trials have all failed. What's next?
While the Western policy debate focuses on vaping and pouches, roughly 100 million people—mostly in South Asia—smoke bidis: cheap, hand-rolled cigarettes that are even more toxic than conventional cigarettes and almost entirely unregulated.
There are hundreds of smoking cessation apps. Most have never been tested. A handful have evidence of effectiveness. The gap between the app stores and the evidence base is a public health opportunity—and a consumer protection problem.
Nicotine is a stimulant that disrupts sleep architecture—but smokers use it to manage the fatigue that poor sleep causes. The nicotine-sleep cycle is a trap that's rarely discussed in cessation counseling, and it should be.
Helping tobacco farmers switch to alternative crops is essential to tobacco control—and extraordinarily difficult to do well. The history of transition programs is a study in good intentions, structural barriers, and the rare successes.
Schools spent millions on bathroom sensors to catch students vaping. But students adapted faster than the technology, and the backlash—from parents, civil liberties groups, and students themselves—is growing.
Every two years, delegates from over 180 countries gather to shape global tobacco policy. The COP is where the FCTC's future is decided—amid industry lobbying, harm-reduction disputes, and the grinding reality of international diplomacy.
Products
Select a product to view details, highlights, and technical specifications.
